Jci_page_head_homepage_01 Jci_page_head_homepage_02
Bernd Baumann, Martin Wagner, Tamara Aleksic, Götz von Wichert, Christoph K. Weber, Guido Adler, Thomas Wirth
Published in Volume 117, Issue 6
J Clin Invest. 2007; 117(6):1502–1513 doi:10.1172/JCI30876
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 7
Etanercept attenuates IKK2-CA–induced pancreatitis in vivo.

(A) Experimental design. Mice were pretreated with etanercept (Etan) 24 hours before injection of Dox and analyzed 24 hours after Dox injection. (B) Immunoblot for IKK2 showed comparable IKK2-CA levels in Ela.rtTA×IKK2-CA mice treated with etanercept and in untreated controls (Con). Single-transgenic IKK2-CA mice did not show relevant amounts of IKK2 upon immunoblot. ERK2 served as loading control. Etanercept treatment (C; control) and Dox injection to single-transgenic IKK2-CA mice (D; 24 hours after Dox) had no effect on pancreatic morphology. (E) Double-transgenic Ela.rtTA×IKK2-CA mice showed signs of pancreatitis 24 hours after Dox injection. (F) This phenotype was not observed in mice pretreated with etanercept. (G) Histology score (n = 3 mice per group).